CTOs on the Move

Bioanalytical Systems

www.basinc.com

 
BASi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. We provide world-class research to the global pharmaceutical industry. Our services include Preclinical Toxicology, Early In Vivo PK, Bioanalysis and a full range of pharmaceutical analysis services. BASi also manufactures innovative scientific instruments including the Culex® Automated In Vivo Sampling System which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. We are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.basinc.com
  • 2701 Kent Ave
    West Lafayette, IN USA 47906
  • Phone: 765.463.4527

Executives

Name Title Contact Details

Similar Companies

Concordant Inc

Concordant Inc is a North Chelmsford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wells Fargo Insurance

Wells Fargo Insurance is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aptuit Informatics

Aptuit Informatics is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hudson Global

Hudson Global is a Tarrytown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Voyager Therapeutics

Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson`s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich`s ataxia, Huntington`s disease, Alzheimer`s Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data.